The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
Top Cited Papers
Open Access
- 29 April 2019
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 25 (4), 676-684
- https://doi.org/10.1111/hae.13762
Abstract
Introduction As a result of the new treatment paradigm that the haemophilia community will face with the availability of novel (non‐factor) therapies, an updated consensus on ITI recommendations and inhibitor management strategies is needed. Aim The Future of Immunotolerance Treatment (FIT) group was established to contemplate, determine and recommend the best management options for patients with haemophilia A and inhibitors. Discussion and Conclusions Despite the considerable success of emicizumab in the management of inhibitor patients, the FIT group still sees the importance of eradicating inhibitors. However, the availability of emicizumab and other non‐factor therapies in the future might impact greatly on how ITI is undertaken. Theoretically, concomitant use of emicizumab and FVIII might allow emicizumab to effectively prevent bleeding with lower dose ITI regimens. This might allow for the greater adoption of low‐dose/low‐frequency FVIII ITI regimens, which may result in a reduced need for central venous access devices while still maintaining a reasonable likelihood of ITI success. The FIT group proposes a new management algorithm for current ITI (without emicizumab) and a hypothetical new approach with the availability of emicizumab. As there are no published data regarding the concomitant use of emicizumab and FVIII for ITI, the FIT Expert group encourages the undertaking of properly conducted prospective studies to explore these approaches further.Keywords
This publication has 36 references indexed in Scilit:
- Inhibitors in patients with haemophilia AThrombosis Research, 2014
- Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF productHaemophilia, 2014
- Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF‐containing plasma‐derived FVIII concentrateHaemophilia, 2013
- How we choose factor VIII to treat hemophiliaBlood, 2012
- The principal results of the International Immune Tolerance Study: a randomized dose comparisonBlood, 2012
- Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomesTherapeutic Advances in Drug Safety, 2011
- The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance inductionThrombosis and Haemostasis, 2011
- Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophiliaHaemophilia, 2010
- International workshop on immune tolerance induction: consensus recommendations1Haemophilia, 2007
- Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort studyBlood, 2007